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Abstract
Tetracyclines (TetraC) are widely used in dermatology for both inflammatory and
infectious dermatoses; recently both in vivo and in vitro studies started to suggest
also a potential antiviral effect. During COVID-19 outbreak, several dermatological
patients contracted SARS-CoV-2 experiencing only mild symptoms, but no protocol
were approved. A multicenter prospective observational study that enrolled COVID-
19 patients visited with teledermatology and undergoing TetraC was performed.
About 38 adult outpatients (M/F: 20/18, age 42.6 years [21-67]) were enrolled. Dur-
ing the TetraC treatment, symptoms resolved in all patients within 10 days. Remark-
ably, ageusia and anosmia disappeared in the first week of TetraC treatment. TetraC
seem a promising drug to treat COVID-19 outpatients with mild symptoms.
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1 | INTRODUCTION
The rapid pandemic spread overwhelmed healthcare systems capacity
worldwide, forcing physicians to quarantine at home both confirmed
and suspected COVID-19 patients with mild respiratory symptoms.1
At the same time, no treatment protocols were approved for these
patients, consequently only a symptomatologic therapy was delivered.
Furthermore, several antivirals and immunomodulators which seem to
have shown anti-COVID-19 effects (ie, lopinavir/ritonavir, tofacitinib
etcetera) are currently recommended by the World Health Organiza-
tion (OMS) only in the context of clinical trials.2 Thus, drug re-
proposal and drug discovery are magnetizing both physician and sci-
entists' efforts for their potential; in silico evaluation and
pharmacoepidemiology play a pivotal role in scanning the possible
candidate against COVID-19.3,4 In this scenario dermatology offers a
wide armamentarium of immunomodulatory and immunosuppressant
drugs that may contrast or even prevent the cytokines storm due to
COVID-19 hyperinflammatory phase.5-8
Remarkably, tetracyclines (TetraC) were candidate as promising
drugs to fight against COVID-19 pandemics due to their potential ant-
iviral effect.9 TetraC represent a wide spectrum polyketide antibiotic
that show a bacteriostatic effect on bacteria, that act through inhibi-
tion of translation and, consequently, the bacterial growth. The first
members of the TetraC group to be discovered were chlortetracycline
and oxytetracycline in the 1940s.
In the following years, the TetraC family has expanded a lot; cur-
rently, it includes more than a dozen molecules. In the dermatological
field, TetraC have been widely used for several decades to treat bothLaura Cristina Gironi and Giovanni Damiani contributed equally to this study.
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infectious and noninfectious diseases (Table 1). As a matter of fact,
TetraC are largely used in dermatology also for their additional prop-
erties, such as antioxidative, immunomodulatory, antiapoptotic, prop-
roliferation, and proangiogenetic ones, to treat several inflammatory
and immunemediated skin disorders summarized in Table S1. Among
TetraC in daily practice, Doxycycline (DOX) and Minocycline (MIN)
are the most prescribed ones due to their safety profile, availability
and efficacy, adequate to treat in an outpatient setting.10 Their pro-
files together with their antiviral property make TetraC an encourag-
ing candidate to treat dermatological outpatients with mild forms of
COVID-19 (Table S2). Furthermore, during the Italian lockdown
(March-May 2020) no pharmacological treatment, unless symptomatic
ones, were approved for mild COVID-19 and patients had to stay in
their home and use telemedicine. Thus, we performed an observa-
tional study on dermatological outpatients with mild COVID-19 and
concurrent dermatoses with TetraC indication.
2 | MATERIALS AND METHODS
2.1 | Rationale
TetraC displayed in humans and animals interesting antiviral proper-
ties not previously tested on Coronaviruses. Furthermore, no thera-
peutic protocols were present for mild COVID-19 outpatients, so
dermatological patients treated with TetraC at home and positive for
SARS CoV-2 represent a unique real-life opportunity to evaluate
in vivo TetraC antiviral properties.
2.2 | Ethical evaluation
The present study fulfilled the ethical principles regarding human
experiments contained in the Declaration of Helsinki and their subse-
quent, included the last one in October 2013. The study received a
full approval by ethical committees of all the involved institutions and
every patient signed an informed consent form.
2.3 | Study design
We performed a multicenter, prospective observational study.
Among all dermatological patients evaluated consecutively with
teledermatology in three primary referral center in Italy (AOU Mag-
giore della Carità in Novara, IRCCS Istituto Ortopedico Galeazzi in
Milan and San Gallicano Dermatological Institute in Rome) during
COVID-19 outbreak (March 9th to May 3rd), we selected the ones
affected by a dermatoses treated at home with TetraC and a concur-
rent certain/suspected COVID-19 diagnosis.
All patients were evaluated according to the clinical, epidemiolog-
ical, laboratory, and radiological criteria of the case definition for
COVID-19 established by European Centre for Disease Prevention
and Control (available at https://www.ecdc.europa.eu/en/covid-19/
surveillance/case-definition). After receiving confirmed or suspected
diagnosis of SARS-CoV-2 infection, all patients were quarantined at
home and followed-up through telemedicine. The visual analog scale
(VAS) has been used to assess cough severity; it consists of a linear
scoring method, where 0 represents no symptom, and 10 indicates
TABLE 1 Main list of the tetracycline in dermatology
TetraC generic name (Abbreviation)
Chemical name PubChem CID
Discovery/first report in the















































Note: Main contraindications: (a) pregnancy (risk of maternal hepatotoxicity, permanent teeth discoloration in the fetus and/or impairment of fetal long bone
growth; (b) children under 8 years of age (mainly for the risk of teeth discoloration and inhibition of bone growth); (c) renal failure (consider dose reduction
and/or increase the interval between doses). Although the calcium of the breastmilk is able to chelate the TetraC and, thus, to reduce the side effects in
infants, they still should not be used breastfeeding. Major adverse events: (a) GI distress (including abdominal discomfort, epigastric pain, nausea, vomiting, and
anorexia); (b) photosensitivity; (c) hepatotoxicity; (d) worsening of preexisting renal failure; (e) intracranical hypertension and/or pseudotumor cerebri.
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the most severe symptom. Patients were also asked to register daily
temperatures and other signs and symptoms.
2.3.1 | Inclusion and exclusion criteria
In this subset, we selected the patients who matched all the following
inclusion criteria: (a) age >18 years; (b) systemic treatment with Tet-
raC for a dermatological disease; (c) signs and symptoms related to
COVID-19 infection. Only not hospitalized patients were considered.
Patients under the age of 18 were excluded, as it is known that SARS-
CoV-2 infection generally has an indolent course in adolescents. Fur-
thermore, we excluded subjects affected by dermatological and
venereological infectious diseases characterized by systemic signs and
symptoms matching those of COVID-19, such as patients simulta-
neously treated with drugs with known or potential antiviral effects
(ie, hydroxychloroquine, azithromycin, lopinavir/ritonavir, etc).
3 | RESULTS
3.1 | Dermatological characteristics of the
enrolled patients
The clinical characteristics of the COVID-19 dermatological patients
described in this report are detailed in Table 2. Globally, we enrolled
38 adult outpatients, affected contextually by a skin disease, and
symptomatic SARS-CoV-2 infection. Patients were 20 females and
18 males, with a mean age of 42.6 years, range 21-67. They were
mainly affected by inflammatory facial dermatoses: 15 had pustular
acne and 11 had pustular rosacea; also, 7 suffered from hidradenitis
suppurativa (HS), while the remaining 5 showed a skin infection
(2 cases of erisipela, 1 impetigo, 1 panniculitis, and 1 folliculitis).
All subjects, due to the skin condition, received the specialist indi-
cations to start TetraC oral therapy. Specifically, we recommended
DOX in 25 cases (200 mg/day for 15 patients, 100 mg daily for the
remaining 10 patients), and MIN in 13 cases (50 mg/day for 8 patients,
100 mg/day in 3 patients, and 200 mg/day in 2 patients).
3.2 | COVID-19-related clinical data
All patients described, developed signs and symptoms referable to
COVID-19 disease within 7 days of the specialist dermatological con-
sultation and were quarantined at home. All cases presented mild
COVID-19 symptoms, which not required hospitalization. In detail,
cough and fever were the most frequent findings, reported by 32 and
31 patients respectively. Cough VAS score never reached the maxi-
mum value for any subject analyzed; fever never exceeded 40C
(37.8C and 39.7C). Bilateral interstitial pneumonia was radiological
observed in 10/17 COVID-19 confirmed cases; dyspnea, fatigue, and
myalgia were reported respectively in 34.2%, 36.8%, and 7.9% of all
patients. Anosmia and ageusia were referred by 12/38 (31.6%) and
9/38 (23.7%) subjects, respectively; bilateral conjunctivitis was pre-
sent in 9/38 subjects, while rhinorrhea, paryngodynia, and chilblain
were reported by 2.6% of cases, respectively.
3.3 | Tetracylines treatment in COVID-19
dermatological patients
No patients reported vomiting or diarrhea. No side effects related to
TetraC therapy were registered, except for mild occasional nausea in
cases treated with the highest doses of DOX.
TABLE 2 Clinical characteristics of COVID-19 confirmed and
suspected dermatological patients in treatment with TetraC
COVID-19
Confirmed cases Suspected cases
Skin disease F/M (%)
Pustular acne 5/3 (47%) 4/3 (33,3%)
Pustular rosacea 3/2 (29.4%) 4/2 (28.6%)
HS 1/0 (5.9%) 2/4 (28.6%)
Skin infection 1/2 (17.7%) 0/2 (9.5%)
Total (F/M) 17 (10/7) 21 (10/11)
Mean age (year) (range) 42.88 (27-66) 42 (21-67)
Signs and symptoms
Fever 17 (100%) 14 (66.6%)
Cough 17 (100%) 15 (71.4%)




Fatigue 9 (52.9%) 5 (23.8%)
Anosmia 8 (47%) 4 (19%)
Ageusia 7 (41.2%) 2 (9.5%)
Bilateral conjunctivitis 4 (23.5%) 5 (23.8%)
Rhinorrhea 1 (5.9%) 0
Myalgia 0 3 (14.2%)
Pharyngodynia 0 1 (4.7%)
Chilblain 0 1 (4.7%)
Tetratracyclines therapy
Doxycycline (%) 13 (76.5%) 12 (57.2%)
100 mg/day 10 0
100 mg bid 3 12
Therapy days,
median (range)
15 (10-30) 22.5 (14-30)
Minocycline (%) 4 (23.5%) 9 (42.8%)
50 mg/day 2 6
100 mg/day 1 2
100 mg bid 1 1
Therapy days,
median (range)
30 (10-30) 30 (15-30)
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During the TetraC treatment, symptoms related to COVID-19
infection completely resolved in all patients within 10 days, range
3-10 days. Remarkably, the body temperature returns to normal
within 4 days in all cases, with a median of 2.5 days. Cough and dys-
pnea also improved rapidly in all patients, with a significant reduction
within 3 days from the beginning of TetraC therapy. Of note, the
higher dosages (200 mg/day both for DOX and MIN) showed faster
response times than lower dosages, in terms of fever, fatigue, and
respiratory symptoms.
The infection-related ageusia and anosmia disappeared in all
patients within 7 days of TetraC treatment.
4 | DISCUSSION
Our real-life data support that TetraC may exert a therapeutic effect
on COVID-19 infection by mitigating mild symptoms. Due to the
COVID-19-related dermatology overwhelming, several patients with
inflammatory and infectious dermatoses were evaluated and treated
by distance especially if they display COVID-19 compatible mild
symptoms.11-15 In this scenario, TetraC represent an ideal treatment
for inflammatory dermatoses for their immunomodulatory properties,
bacterial infections for their antibacterial effect and mild forms of
COVID-19 for their antiviral effect. In literature a growing body of
data prove TetraC direct and indirect antiviral effects and postulate
their use in coronavirus-induced human diseases (Table S2).
Among all tetracyclines family, DOX and MIN have the stronger
antiviral evidence demonstrating their inhibition on viral replication
exerted on several human and animal RNA viruses.1,16-27 In 2001,
Aurisicchio et al demonstrated in C57/B6 mice infected with a lethal
dose of coronavirus that DOX induces antiviral genes expression via
IFN(alpha), findings replicated also in Porcine Reproductive and Respi-
ratory Syndrome virus (PRRSV), two Coronaviruses belonging to the
gender of Nidovirales.27,28
Recently, Wu et al in a computational study focusing on new
therapeutic targets for SARS-CoV-2 found that DOX and other Tet-
raC (lymecycline, demeclocycline, and oxytetracycline) display high
binding affinity to the 3-chymotrypsin-like protease (3CLpro), an
enzyme that plays a pivotal role in SARS-CoV-2 replication.1 Two fur-
ther computational, drug-repurposing studies also suggested that Tet-
raC (DOX, MIN, TetraC, Demeclocycline, and Eravacycline) may play a
key role in antagonizing SARS-CoV-2 main proteases.20,28 Moreover,
He et al demonstrated in vitro that COL-3, a chemically modified tet-
racycline, directly modify the expression of several pro-inflammatory
cytokines and chemokines (ie, Tumor Necrosis Factor-alpha [TNF-α]
in HCC515 line of human lung cells treated with ACE2 inhibitor, theo-
retical application in COVID-19-related lung injury disease.21
Our results, together with the existing literature, may also enforce
the idea that TetraC exert indirect antiviral effect mediated by immu-
nomodulatory, antiinflammatory, antiapoptotic/antioxidant properties.
TetraC immunemodulation inhibits neutrophil chemotaxis, alter endo-
thelial permeability by Matrix Metalloproteinases (MPPs) MMP-2 and
MMP-9, decrease proinflammatory cytokines (ie, TNFα, IL1β)
production, and release by both neutrophils M1 macrophages, both
infiltrating COVID-19 patients' alveoli. Specifically, DOX reduces
proinflammatory cytokines (ie, IL-6, IL-1, IL-8, and TNF-α), results with
a great clinical relevance especially in viral infections with a prominent
inflammatory reaction, as dengue.29-31 Fredeking et al evaluated
231 patients with dengue hemorrhagic fever treated with DOX (twice
daily for 7 days) and observed a significant lower mortality concurrent
with lower serum levels of TNF and IL-6 compared with age-matched
and sex-matched controls.32
These findings are promising also for severe COVID-19 patients
in which IL-6 is the main driver of the “cytokinic storm” and conse-
quent mortality, as testified by the encouraging results obtained using
tocilizumab, an IL-6 receptor inhibitor, on lung lesions.33 Furthermore,
TetraC also inhibits high-mobility group box 1 protein (HMGB1), a
cytokine that polarizes macrophages in the proinflammatory line
(M1) during lung inflammation.34 HMGB1 binds TLR2 and TLR4
increasing TNFα, IL1β, and IL-6 transcription.34,35 Together with
chronic obstructive pulmonary disease (COPD), also obese patients
display higher IL-6 serum level and increased mortality, so TetraC may
be considered also in mild COVID-19 patients with comorbidities
increasing IL-6 production.
Then, TetraC antiinflammatory effect via phospholipase A2 inhibi-
tion and Ca2+ dependent and independent antioxidant/antiapoptotic
effect further suggest including tetracycline in the COVID-19
armamentarium.35-37.
Our study described in detail the effect of TetraC mon-
otherapy in 38 mild COVID-19 outpatients in therapy for pre-
existing inflammatory dermatological skin disorders and suggest a
potential beneficial effect. Currently, only Bonzano et al reported a
sudden improvement of COVID-19 symptoms, including anosmia,
in 6 patients treated with DOX 200 mg/day at least for 8 days.22 In
our larger cohort, both DOX and MIN rapidly improved symptoms
in all patients in a dose dependent manner within 10 days, whereas
the average duration of symptoms reported in the literature in
COVID-19 patients quarantined at home is approximately
20 days.38 Remarkably, no drug-induced adverse events were
recorded in COVID-19 patients undergoing TetraC. In fact, TetraC
are easy to handle drugs, which can be used on also large cohorts
of home patients without special precautions, except for pregnant
and breastfeeding women and in children less than 8 years. Further
studies are mandatory to evaluate TetraC as potential drug in mild
COVID-19 outpatients.
To the best of our knowledge, this report presents the first real-
life experience regarding the potential use of DOX and MIN as mon-
otherapy in nonhospitalized mild COVID-19 patients. Our preliminary
observation suggests that TetraC, specifically DOX and MIN, may mit-
igate COVID-19 related mild symptoms (ie, cough).
Due to their low toxicity, high safety profile, and costs, TetraC
should be considered in the armamentarium during COVID-19 out-
break for outpatients with mild forms. Further studies, as well as a
rapid screening algorithm to evaluate by distance possible COVID-19
patients, are warranted to improve teledermatology and telemedicine
during pandemics.
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